References For "Did You Know?" Facts:
- After using RESTASIS® for 2 months, 85% of patients planned to continue using RESTASIS® Ophthalmic Emulsion. (n=1,868 )
- Data on file, Allergan, Inc.
- Only 5 out of 293 patients in clinical trials discontinued RESTASIS® due to burning and stinging
- Sall K, Stevenson OD, Mundorf, Reis BL, and the CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000;107(4):631-639.
- Chronic Dry Eye is the most common patient complaint in the ophthalmologist's office
- Stevenson D, Tauber J, Reis BL, and The Cyclosporin A Phase 2 Study Group. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. Ophthalmology. 2000;107:967-974.
- While estimates vary, at least 3.2 million women in the U.S. suffer from Chronic Dry Eye
- Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:2318-2326.
- Patients may have already tried several brands of artificial tears.
- Multi-Sponsor Surveys, Inc. The 2008 Gallup Study of Dry Eye Sufferers. Summary Volume. July 2008.
- 97.9% of patients with commercial insurance have reimbursement coverage for their RESTASIS® prescriptions.
- Data on file, Allergan, Inc.
